Sponsored by Acclaro Corp.
UltraClearTM, from Acclaro Corp. (formerly FA International LP, Boston, Mass.), is reportedly the world’s first cold ablative fiber aesthetic laser. As a flagship FDA-cleared skin rejuvenation system, UltraClear is breaking new ground as a powerful, no-downtime, painless therapy for the entire spectrum of anti-aging skin conditions, including age spots, enlarged pores, fine lines and wrinkles, scars and acne scars, stretch marks, sun damage, textural irregularities and general complexion issues. Most treatments do no require topical numbing. The device it is safe for all skin types and is emerging as a leader for treating Asian and darker skin types (III – VI), specifically. The 2910 nm wavelength is at water peak absorption, maximizing tissue ablation and minimizing incidence of post-inflammatory hyperpigmentation (PIH) or post-inflammatory erythema (PIE), as well as bleeding.
Aesthetic laser innovator and Acclaro president, Shlomo Assa (Smithfield, R.I.), is the inventor of UltraClear. According to Mr. Assa, fiber lasers are the future of laser technology, “because they are more reliable with superior beam quality and speed. It is ‘cold’ relative to other lasers because tissue is vaporized so efficiently by the non-visible 2910 nm wavelength. There are no lingering thermal traces, which reduces the potential for pain, especially in the stratum corneum where there are no nerves when using the Clear Mode of the device. Furthermore, UltraClear offers an optimized solution that increases clinical efficacy while reducing risks and improving the overall patient experience.
“Painlessness with deeper penetration of energy using Ultra Mode is a product of engineering,” Mr. Assa continued. “The fiber laser delivers superb beam quality, allowing us to create a very tight, high-density spot to maximize the effect but minimize the total energy delivered because of the small individual spot. We combine this with rapid fractionated pulsing, so there is not enough energy for the nerves to feel anything. The laser can rapidly deliver a high-resolution pattern of these small spots within the tiniest fraction of the time required with an older generation laser. The patent pending blended pulse technology 3DIntelliPulseTM creates profound, three-dimensional collagen remodeling by automatically blending cold and thermal energy simultaneously at the same micro-ablative channels and delivering fractional coagulation at multiple skin layers to optimize efficacy while increasing safety for all skin types.”
With treatment times under 15 minutes, no topical numbing required for most procedures, no consumables, or per-pulse payments, throughput is high and return on investment (ROI) is rapid. Safety and ease of use make it prime for delegation to trained ancillary staff.
Eric F. Bernstein, MD, chief medical officer of Acclaro and medical director of his practice, Main Line Center for Laser Surgery (Ardmore, Pa.), led a histopathology study of the effects of the UltraClear laser (publication pending). “With UltraClear you can get a very superficial injury, which, under the microscope, is limited to the stratum corneum and not even, or barely, into the epidermis,” he explained. “However, we see significant erythema and a dermal inflammatory response followed by a remarkable clinical effect. The end result is, simply put, a significant clinical ‘rejuvenation’ outcome with minimal superficial injury to the skin.”
Dr. Bernstein added that Clear Mode was used in this study, and studies with Ultra Mode and UltraClear mode are ongoing. “We could rapidly treat the whole face without pain, using the 15 mm x 15 mm spot which was very easy to use. My Ultra Mode study uses no topical anesthetic, and I have completed the first treatment in that study already. I have been very impressed with the UltraClear laser. This is a leap forward technology in my opinion. I have been waiting for a device like this for a long time.”